Therapeutic Optionality

The project demonstrates exceptional therapeutic optionality across multiple dimensions. It spans three distinct therapeutic lanes (longevity, nootropics, peptides) with over 80 individual hypothesis cards covering: (1) Longevity — at least 32 cards (L1–L32) addressing rapamycin mTORC2 tissue selectivity, senolytic biomarker validation, NAD/CD38 combination pharmacology, epigenetic clock concordance, and mechanism-of-action insufficiency tests for 17α-estradiol, acarbose, spermidine, urolithin A, metformin, lithium, canagliflozin, resveratrol, melatonin, FGF21, taurine, α-ketoglutarate, BHB, L-lactate, and succinate. (2) Nootropics — at least 32 cards (N1–N32) covering modafinil/DAT, methylene blue/MAO-A vs redox, creatine/PCr, Lion's mane/NGF, L-theanine/adenosine, Rhodiola/HPA, Bacopa/AChE, nicotine/nAChR, L-tyrosine/catecholamine, guanfacine/α2A, caffeine/A2A, atomoxetine/NET, fluoxetine/SERT, rolipram/PDE4, memantine/NMDAR, sarcosine/GlyT1, aniracetam/AMPAR, buspirone/5-HT1A, baclofen/GABA-B. (3) Peptides — at least 30 cards (P1–P30) covering BPC-157, thymosin β4, MOTS-c, humanin, SS-31, ARA-290, Semax, Selank, Dihexa, oxytocin, Exendin-4, ghrelin, PACAP, NPY, VIP, orexin-A, CGRP, plus the EGFR computational binder campaign. The breadth of targets, mechanisms, and therapeutic areas is extraordinary for a TRL 1 project, providing maximum flexibility for pivoting based on early experimental results. Each card is independently actionable with defined kill criteria and estimated 4–6 week refute timelines.

Intellectual Property

The IP position is mixed. On the positive side: (1) The EGFR computational binder campaign targets a novel EGF-competitive DI/DIII epitope (explicitly excluding the Cetuximab/Domain IV epitope), with 4 structurally diverse designs across 4 clusters from 2 engines (rfd3, boltzgen), suggesting potential novelty for patenting if validated. (2) The 'subtract-before-add' framework for NAD/senolytic combination pharmacology (L5–L13) represents a conceptually novel ordering/sequencing approach. (3) The systematic 'assumption-kill' methodology across ~80+ hypothesis cards creates a novel experimental framework, though the framework itself may be harder to patent than specific molecular findings. (4) Several specific mechanistic claims are novel (e.g., BPC-157 FBXO22 vs VEGFR2 ECD binding, LKKTETQ sequestration insufficiency). On the negative side: (1) FTO status is explicitly UNKNOWN across all cards — no freedom-to-operate analysis has been performed. (2) No patents have been filed or granted. (3) Most hypothesis cards test existing compounds (rapamycin, metformin, caffeine, etc.) against known targets, limiting composition-of-matter IP. (4) The EGFR binder designs are computational predictions only with no measured binding — IP value is speculative until validated. (5) Many of the 'assumption-kill' experiments, if successful, would generate negative results (showing a mechanism is insufficient), which are harder to patent than positive discoveries. (6) The ip_class designations (subtract-before-add, redox-vs-MAO, momp-execution-gate, etc.) suggest awareness of IP positioning but no formal IP strategy is documented. (7) Significant prior art exists for all target areas. The concept is novel enough for potential patenting in specific areas (EGFR binders, combination ordering), but substantial prior art risk exists and no IP protection has been initiated.